Galderma Group AG (XSWX:GALD) Ending Cash Position: CHF622 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GALD Galderma Group AG XSWX:GALD
14 GF Score
Price CHF172.50
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Ending Cash Position?

Galderma Group AG XSWX:GALD +1.53% 14 Ending Cash Position is CHF622 Mil as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Galderma Group AG's Ending Cash Position for the quarter that ended in Dec. 2025 was CHF622 Mil.

Galderma Group AG's quarterly Ending Cash Position declined from Dec. 2024 (CHF407 Mil) to Jun. 2025 (CHF372 Mil) but then increased from Jun. 2025 (CHF372 Mil) to Dec. 2025 (CHF622 Mil).

Galderma Group AG's annual Ending Cash Position increased from Dec. 2023 (CHF318 Mil) to Dec. 2024 (CHF407 Mil) and increased from Dec. 2024 (CHF407 Mil) to Dec. 2025 (CHF622 Mil).

Galderma Group AG Ending Cash Position Related Terms

Galderma Group AG Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Ending Cash Position Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
270.41 218.09 318.25 407.46 621.58

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial 318.25 344.11 407.46 372.45 621.58
XSWX:GALD
14GF Score
Galderma Group AG XSWX:GALD
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Galderma Group AG's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=364.183+257.399
=622

Galderma Group AG's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=364.98+256.602
=622

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of CHF622 Mil mean?
Galderma Group AG (XSWX:GALD) has a Ending Cash Position of CHF622 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Ending Cash Position too high?
Galderma Group AG's current Ending Cash Position is CHF622 Mil. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Ending Cash Position compare to ZTS and UTHR?
Galderma Group AG's Ending Cash Position of CHF622 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Ending Cash Position is CHF622 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Ending Cash Position of CHF622 Mil. The current Ending Cash Position is CHF622 Mil. Galderma Group AG's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Ending Cash Position is CHF622 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score

Get the complete analysis for XSWX:GALD

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF172.50
Price